Adaptogen Raw Material Testing: The Authentication Failures in Your Ashwagandha, Rhodiola, and Ginseng Supply Chain

Ashwagandha generates more than $200 million in annual US retail sales. Rhodiola and ginseng push that figure considerably higher. Every major natural products retailer carries adaptogen SKUs now — stress support, cognitive performance, hormonal balance — and the category continues to grow at roughly 8% year-over-year.

The quality infrastructure supporting that growth hasn’t kept pace. The adaptogen raw material supply chain — concentrated in India for ashwagandha and in China for much of the rhodiola and ginseng — runs on supplier Certificates of Analysis that were never designed to catch the most common failure modes. And the failures we see in incoming lots aren’t always outright fraud. Some of them are structural problems baked into how these materials are grown, collected, and certified before they leave the country of origin.

We test adaptogen raw materials regularly through our Chicago-area intake facility, with full analytical panels completed at our ISO 17025–accredited laboratory on the West Coast. The pattern of findings is consistent enough that it’s worth mapping out — because a lot of Midwest supplement brands are unknowingly building finished products on a foundation of questionable identity.

Here’s what the data actually looks like at the testing bench.

Ashwagandha: Withanolide Dilution and the Species Overlap Problem

Withania somnifera root powder and root extract are the two dominant forms on the US market. Most commercial specifications require a minimum of 5% withanolides — the steroidal lactones responsible for ashwagandha’s adaptogenic activity — with premium extracts targeting 8–10%.

The supplier CoA commonly says 5.2%. Our HPLC says 2.7%.

That gap isn’t a one-off anomaly. It’s common enough to be a planning assumption. At 2.7% withanolides in a 300 mg capsule, you’re delivering less than half the active compound the label implies. The formula may still pass basic finished product QC because most internal testing panels don’t include marker compound quantification on finished goods. But if a brand is making a structure/function claim tied to withanolide content — which many do, explicitly or implicitly — that claim is built on incoming data the brand has never independently verified.

Part of the problem is taxonomic. Withania somnifera isn’t the only species in the genus, and other Withania species produce withanolide profiles that partially overlap with W. somnifera under basic chemical testing. A single-marker HPLC that confirms “withanolides detected” can pass material blended with starch carrier or sourced from a related species. HPTLC fingerprinting against a validated W. somnifera reference standard — following USP or American Herbal Pharmacopoeia methodology — produces a characteristic multi-band pattern that deviates detectably when substitution or blending has occurred.

Identity testing and potency testing are two distinct analytical steps. Skipping either one means working with an incomplete picture.

Rhodiola Rosea: The Species Substitution the CoA Won’t Show You

This is the category where we see the most consistent and systematic adulteration, and it has a structural cause rooted in market economics.

Rhodiola rosea is the species with the clinical evidence behind it. A widely cited meta-analysis published in Phytomedicine reviewed 11 randomized controlled trials on R. rosea and found significant effects on physical performance and mental fatigue. Every one of those studies was conducted on material characterized by its rosavin content — specifically rosarin, rosavin, and rosin — alongside salidroside. The industry-standard commercial specification is 3% rosavins and 1% salidroside, reflecting the ratio naturally present in authentic R. rosea root.

Rhodiola crenulata grows in greater abundance across parts of China and Tibet and costs substantially less to source. It contains meaningful salidroside. It contains essentially no rosavins.

A supplier who tests only salidroside content — 1% being the typical spec minimum — can pass R. crenulata material against a R. rosea specification without triggering a failure. The CoA reports 1.1% salidroside. Passes. Ships. The finished product label says “Rhodiola rosea, standardized to 3% rosavins, 1% salidroside.” The incoming material has zero detectable rosavins. No fraud has technically occurred in the supplier’s own testing protocol — they just tested the wrong marker against an inadequate specification.

HPTLC against an authentic R. rosea reference reveals a rosavin band cluster in the mid-to-upper portion of the chromatogram that is simply absent in R. crenulata material. That absence is diagnostic. Pair that with DNA barcoding — using ITS2 or matK/rbcL markers — and you get definitive species identification regardless of how heavily processed the extract is. HPTLC alone can miss degraded or heavily hydrolyzed extracts; DNA alone doesn’t confirm marker compound presence. Together, they close the loop. Neither method is optional if the finished product carries a species-specific identity claim.

Panax Ginseng: Ginsenoside Profiling and the Persistent Misidentification Problem

Panax ginseng and Panax quinquefolius are true ginsengs. Their active markers — ginsenosides — have a well-characterized HPLC profile, and the two species show distinct ginsenoside ratios that allow differentiation. A standardized 5% ginsenoside extract should present a specific chromatographic fingerprint, not just a sum-total number.

The more persistent raw material problem is substitution with Eleutherococcus senticosus, sold for decades under the trade name “Siberian ginseng.” It’s not a Panax species. It doesn’t contain ginsenosides — it contains eleutherosides, a structurally different class of compounds with a separate clinical evidence base. The two plants are not botanically close beyond both belonging to the Araliaceae family. But because the “ginseng” common name became commercially attached to Eleutherococcus through decades of marketing, sourcing confusion — or deliberate substitution — does occur at the raw material level.

Any incoming lot of claimed Panax ginseng should return Panax genus identification on DNA barcoding and a characteristic ginsenoside HPLC chromatogram with expected peak ratios. When lots arrive and return Eleutherococcus on DNA and absent ginsenoside peaks on HPLC simultaneously, that’s substitution at the source — not a processing artifact.

For American ginseng specifically: P. quinquefolius wild-harvested material carries CITES Appendix II protection status. Brands making American ginseng claims tied to wild origin or geographic provenance carry additional documentation requirements that extend well beyond a standard supplier CoA.

Why the Standard CoA Consistently Misses These Failures

A CoA from an overseas supplier tells you what they found using their own methods on their own sample — it doesn’t tell you what’s in the bag you received.

That’s not a criticism of suppliers as a category. It’s an accurate description of what the document was designed to do. Most supplier CoAs for botanical raw materials test identity through organoleptic evaluation (appearance, odor, texture) plus one or two marker compound assays — occasionally a TLC plate, rarely anything more rigorous. Validated HPTLC against a pharmacopeial reference standard requires method validation infrastructure that most origin-country suppliers don’t maintain. DNA barcoding on processed extracts requires molecular biology capacity that is even less common.

The supplier’s CoA can accurately report what it tested. The problem is that what it tested isn’t sufficient to catch species substitution, marker dilution, or blending with lower-value materials.

The regulatory dimension compounds this gap. Under 21 CFR Part 111.75 — the FDA’s cGMP rule for dietary supplements — finished product manufacturers must establish the identity of every incoming raw material before it enters production. The rule does permit reliance on a supplier’s CoA for identity verification, but with a condition that most brands overlook: the manufacturer must have “established the reliability of the supplier’s certificate of analysis” through a defined qualification process, including periodic verification testing. That’s not a passive document review. It’s an active analytical validation program.

Form 483 observations citing inadequate incoming raw material identity testing appear regularly in FDA inspection records made public through FOIA requests. It’s one of the most common cGMP findings in dietary supplement facilities. And when a finished product recall traces back to an incorrectly identified raw material, the absence of a defensible incoming testing program becomes the central exhibit in the regulatory response.

Building an Incoming Test Protocol That Actually Works

For ashwagandha, rhodiola rosea, or ginseng, a defensible raw material testing protocol includes five elements:

Botanical identity by HPTLC — fingerprinting against a validated reference standard following USP, AHP, or in-house validated methodology. This is the minimum identity step; it confirms the presence of expected chemical classes and detects deviations consistent with substitution or adulteration.

Species confirmation by DNA barcoding — ITS2 sequencing is the current standard for most botanical materials; matK/rbcL provides supplementary confirmation on difficult matrices. Critical for processed extracts where morphological identity is no longer available.

Marker compound quantification by HPLC — withanolides for ashwagandha, rosavins plus salidroside for rhodiola rosea, ginsenoside profiling for ginseng. This is the potency verification step and the analytical foundation for any label claim tied to active content.

Heavy metals by ICP-MS per USP <232>/<233> — adaptogens from Ayurvedic and traditional Chinese medicine supply chains carry documented lead, cadmium, and arsenic contamination risk. It’s not optional for any Ayurvedic-origin herb or any material sourced from regions with known agricultural soil contamination.

Microbiology per USP <61>/<62> — total aerobic plate count, yeast and mold, and specified organism absence (Salmonella, E. coli, Staphylococcus aureus). Botanical powders are a high-risk microbiology category; incoming raw material screening is significantly cheaper than a finished goods rejection.

Five analytical methods per lot sounds like a significant investment until you run one compromised lot through a full production cycle and encounter it on a third-party shelf audit or an FDA inspection.

Before Your Next Production Run

If you’re sourcing adaptogen raw materials — from a domestic distributor, a US-based broker, or direct from an overseas manufacturer — the time to verify identity and potency is before production, not after it.

Our Chicago-area receiving facility in Countryside, IL accepts raw material samples from supplement brands across Illinois, Indiana, Wisconsin, and Michigan. Standard analytical panels return ISO 17025–accredited Certificates of Analysis in 5–7 business days. For brands operating on quarterly production schedules, that timeline integrates cleanly without disrupting a production date.

The adaptogen market isn’t slowing. Neither is FDA scrutiny of incoming raw material documentation. Getting the testing right on incoming lots isn’t an add-on step — it’s the one that determines whether everything downstream holds up.

---

Written by Nour Abochama, VP Operations, Qalitex | Quality Consultant, Ayah Labs. Learn more about our team

Ship your sample to our Chicago facility — get a Qalitex CoA in 5–7 days. Contact us

Related from our network

• ISO 17025-Accredited Raw Material Testing for Supplement Brands — HPTLC, DNA barcoding, ICP-MS, and HPLC marker quantification under ISO 17025 accreditation for incoming botanical ingredient verification.
• DSHEA Compliance Testing and Supplier CoA Verification — Third-party analytical support for 21 CFR Part 111 incoming material identity requirements, including supplier qualification documentation.